Jubilant Pharmova Q4 Review - Big Miss; Recovery Delayed: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Jubilant Pharmova Ltd.'s Q4 FY21 performance was below our estimates with miss of 12/25/21% in revenue/Ebitda/PAT.
The life science ingredients business got demerged into Jubilant Ingrevia Ltd. from February 2021.
Pharma business revenue remained flat at Rs 15.8 billion, Ebitda margin dropped 420 basis points year-on-year to 23.7% and adjoining PAT declined 13.7% to Rs 1.8 billion.
The contract development and manufacturing business benefited from the manufacturing of potential Covid-19 drug and vaccines which contributed Rs 5.4 billion revenue in FY21.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.